KEPPRA

Peak

levetiracetam

NDAORALTABLET
Approved
Nov 1999
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be…

Clinical Trials (5)

NCT04836559Phase 2Completed

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Started May 2021
110 enrolled
Focal Onset Seizures
NCT03489044Phase 2Completed

An Investigation of Levetiracetam in Alzheimer's Disease

Started Oct 2018
8 enrolled
Alzheimer DiseaseEpilepsy
NCT03340064Phase 3Completed

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

Started Nov 2017
38 enrolled
Partial Seizures
NCT02602860Phase 1Completed

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

Started Nov 2015
13 enrolled
Healthy Volunteers
NCT02201251Phase 3Completed

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

Started Oct 2014
63 enrolled
Epilepsy

Loss of Exclusivity

LOE Date
Dec 7, 2031
70 months away
Patent Expiry
Dec 7, 2031

Patent Records (2)

Patent #ExpiryTypeUse Code
8802142
Jun 7, 2031
Product
8802142*PED
Dec 7, 2031